Abstract
A mechanism-based pharmacodynamic model was used to describe the inhibitory effect by omeprazole on gastric acid secretion measured after histamine stimulation in the dog. The model identifies parameters that are related to the physiological system, the histamine stimulation, and the irreversible effect of omeprazole on the H+, K+-ATPase enzyme. Four different experiments with omeprazole (Exps. 1–4) and two placebo experiments were performed in each of the four Heidenhain pouch dogs used. For placebo and experiments 1–3, saline or omeprazole 0.81 μmol/kg was infused during 3 hr with measurements of histamine-stimulated gastric acid secretion in two periods of 3.5–6.5 hr, one period starting just before the omeprazole infusion and a second later period up to 29 hr post infusion. In experiment 4, 0.18 μmol/kg of omeprazole was infused for 22.5 min and gastric juice was collected for 5 hr post infusion. The response data was well described by the model. Similar parameter estimates were obtained by three different analysis methods; naïve pooling, two-stage method and nonlinear mixed effects modeling. The elimination rate constant for the H+, K+-ATPase enzyme, k out, was estimated to be 0.040 hr-1, corresponding to a half-life of about 17 hr. This rate constant determines the duration of omeprazole inhibition after long-term exposure. For short-term omeprazole exposure the duration is determined by the rate constant for transfer of enzymes from active to resting state, estimated to be 1.88 hr-1. The second-order rate constant for histamine stimulation was estimated to be 0.064 hr-1 per histamine concentration unit and the maximum acid secretion was estimated to be 5.0 mmol H+/30 min. The second-order rate constant for the irreversible binding of omeprazole to H+, K+-ATPase, k ome, was estimated to be 2.39 L/μmol ⋅ hr. By modeling the histamine-induced baseline response simultaneously with active treatment, predictions of the response are possible not only following different dosing regimens of omeprazole, but also following different degrees of histamine stimulation.
Similar content being viewed by others
REFERENCES
B. Wallmark, B. M. Jaresten, H. Larsson, B. Ryberg, A. BrÄndström, and E. Fellenius. Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN¯ on gastric acid secretion. Am. J. Physiol. 245:G64–71 (1983).
P. Lorentzon, R. Jackson, B. Wallmark, and G. Sachs. Inhibition of (H++K+)-ATPase by omeprazole in isolated vesicles requires proton transport. Biochim. Biophys. Acta 897:41–51 (1987).
D. J. Keeling, C. Fallowfield, and A. H. Underwood. The specificity of omeprazole as an (H+-K+)-ATPase inhibitor depends upon the means of its activation. Biochem. Pharmacol. 36:339–344 (1987).
A. J. Pope and M. E. Parsons. Reversible inhibitors of the gastric (H+/K+)-transporting ATPase: a new class of antisecretory agents. Trends Pharmacol. Sci. 14:323–325 (1993).
S. J. Hersey and G. Sachs. Gastric acid secretion. Physiol. Rev. 75: 155–189 (1995).
A. Äbelö, U. G. Eriksson, M. O. Karlsson, H. Larsson, and J. Gabrielsson. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J. Pharmacol. Exp. Ther. 295:662–669 (2000).
H. Larsson, M. L. Berglund, and E. Carlsson. Omeprazole-the relation between plasma levels and gastric antisecretory effect in the dog. Abstract, Acta Physiol. Scand. Suppl.508:66 (1982).
H. Larsson, E. Carlsson, U. Junggren, L. Olbe, S.E. Sjöstränd, I. Skånberg, and G. Sundell. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterol. 85:900–907 (1983).
P. O. Lagerström and B. A. Persson. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. Chromatogr. 309: 347–356 (1984).
B. N. Halpern, T. Neveu, and C. W. M. Wilson. The distribution and fate of radioactive histamine in the rat. J. Physiol. 147:437–449 (1959).
S. L. Beal and L. B. Sheiner. NONMEM Users Guide, NONMEM Project Group, University of California, San Francisco, 1992.
E. N. Jonsson and M. O. Karlsson. Xpose-an S-Plus based population pharmacokinetic/ pharamacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58(1):51–64 (1999).
D. R. Scott, H. F. Helander, S. J. Hersey, and G. Sachs. The site of acid secretion in the mammalian parietal cell. Biochim. Biophys. Acta 1146:73–80 (1993).
J. De Graef and M. C. Woussen-Colle. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterol. 91:333–337 (1986).
K. Gedda, D. Scott, M. Besancon, and G. Sachs. The half life of the H,K ATPase of gastric mucosa. Gastroenterol. 109:1134–1141 (1995).
G. Sachs, J. M. Shin, C. Briving, B. Wallmark, and S. Hersey. The pharmacology of the gastric acid pump: The H+, K+. Annu. Rev. Pharmacol. Toxicol. 35:277–305 (1995).
T. Lind, C. Cederberg, G. Ekenved, U. Haglund, and L. Olbe. Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 24:270–276 (1983).
P. Olsson Gisleskog, D. Hermann, M. Hammarlund-Udenaes, and M. O. Karlsson. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α reductase inhibitors GI198745 and finasteride. Clin. Pharmacol. Ther. 64:636–647 (1998).
M. Hassan, U. S. H. Svensson, P. Ljungman, B. Bjö rkstrand, H. Olsson, M. Bielenstein, M. Abdel-Rehim, C. Nilsson, M. Johansson, and M. O. Karlsson. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 48:669–677 (1999).
V. I. Avramis, S. Sencer, A. P. Periclou, H. Sather, B. C. Bostrom, L. J. Cohen, A. G. Ettinger, L. J. Ettinger, J. Franklin, P. S. Gaynon, J. M. Hilden, B. Lange, F. Majlessipour, P. Mathew, M. Needle, J. Neglia, G. Reaman, and J. S. Holcenberg. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99:1986–1994 (2002).
M. Katashima, K. Yamamoto, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole, lansoprazole and pantoprazole, in humans. Eur. J. Drug. Metab. Pharmacokinet. 23:19–26 (1998).
T. Rydberg, A. Jonsson, M. O. Karlsson, and A. Melander. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43(4):373–378 (1997).
E. N. Jonsson, J. R. Wade, and M. O. Karlsson. Nonlinearity detection: advantages of nonlinear mixed effects modelling. AAPS Pharmsci. 2(3) article 32 (2000).
B. K. Kataria, S. A. Ved, H. F. Nicodemus, G. R. Hoy, D. Lea, M. Y. Dubois, J. W. Mandema, and S. L. Shafer. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology. 80(1):104–122 (1994).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Äbelö, A., Holstein, B., Eriksson, U.G. et al. Gastric Acid Secretion in the Dog: A Mechanism-Based Pharmacodynamic Model for Histamine Stimulation and Irreversible Inhibition by Omeprazole. J Pharmacokinet Pharmacodyn 29, 365–382 (2002). https://doi.org/10.1023/A:1020905224001
Issue Date:
DOI: https://doi.org/10.1023/A:1020905224001